Global drug pricing: How cost-effective is bevacizumab?

Bookmark and Share
Published: 6 Jun 2016
Views: 1792
Dr Daniel Goldstein - Emory University, Atlanta, USA

Dr Goldstein speaks with ecancer at ASCO 2016 about his research into global drug pricing, with specific focus on the cost-effectiveness of bevacizumab.

In the United States, the addition of bevacizumab to 1st-line chemotherapy in metastatic colorectal cancer provides an additional 0.10 quality-adjusted life years (QALYs) at an incremental cost-effectiveness ratio (ICER) of $571,240/QALY.

With this as a comparative value, he sets out the international variation of treatment cost, and discusses the potential drivers of economic fluctuations.

Addressing the wider variability of drug pricing between countries, he examines the relation between drug availability and GDP.